PCNA

Proliferating cell nuclear antigen · P12004 · PCNA on Sugi Atlas →

4,097 patent compounds predicted against PCNA, 2,928 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4001279	0.56	17/20
SCHEMBL4002336	0.51	17/20
SCHEMBL282369	0.57	15/20
SCHEMBL282577	0.53	15/20
SCHEMBL282148	0.52	15/20
SCHEMBL1115191	0.52	15/20
3,5-Diiodothyropropionic Acid (SCHEMBL1501771)	1.00	14/20
SCHEMBL4005004	0.66	14/20
SCHEMBL4004003	0.58	14/20
SCHEMBL4449390	0.74	13/20
SCHEMBL4008454	0.61	13/20
SCHEMBL4428790	0.52	12/20
SCHEMBL1525946	0.54	11/20
Thyropropic Acid (SCHEMBL310201)	1.00	10/20
SCHEMBL4238471	0.65	10/20
Tiratricol (SCHEMBL25149)	1.00	9/20
Tiratricol (SCHEMBL743426)	1.00	9/20
Tiratricol (SCHEMBL2671904)	0.97	9/20
Tiratricol (SCHEMBL1652870)	0.77	9/20
SCHEMBL4439596	0.77	9/20

Clinical trials — most relevant to PCNA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma	PHASE2/PHASE3	UNKNOWN
Intracameral Antibiotic Safety Study	PHASE3	SUSPENDED
Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization	PHASE2/PHASE3	COMPLETED
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis	PHASE2	COMPLETED
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	PHASE2	RECRUITING
Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration	PHASE2	UNKNOWN
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery	PHASE2	COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer	PHASE2	UNKNOWN
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers	PHASE2	COMPLETED
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer	PHASE1	COMPLETED
Doxil Topotecan Doublet Cancer Study	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer	PHASE1	COMPLETED
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
New Strategies Against Cutaneous Squamous Cell Carcinoma	nan	COMPLETED
Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients	nan	COMPLETED
Freeze-Dried Black Raspberries in Treating Patients With Oral Squamous Cell Cancer Undergoing Surgery	nan	COMPLETED
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED
Telomere and Telomerase	nan	WITHDRAWN
Characterization of Sperm Population Following Different Selection Procedures	nan	UNKNOWN
Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PCNA binder may also engage these)

Protein	Name	Similarity
Q9DDF1	—	1.000	Q9DDF1 →
Q9DEA3	—	1.000	Q9DEA3 →
P61258	—	1.000	P61258 →
Q3ZBW4	—	1.000	Q3ZBW4 →
Q9PTP1	—	1.000	Q9PTP1 →
P57761	—	1.000	P57761 →
P04961	—	1.000	P04961 →
Q6B6N4	—	1.000	Q6B6N4 →
Q9W644	—	1.000	Q9W644 →
P17918	—	1.000	P17918 →
P53358	—	0.997	P53358 →
P18248	—	0.996	P18248 →
O01377	—	0.996	O01377 →
G0SF70	—	0.996	G0SF70 →
P17917	—	0.996	P17917 →
P17070	—	0.995	P17070 →
O82797	—	0.995	O82797 →
Q9ZW35	—	0.995	Q9ZW35 →
Q43124	—	0.995	Q43124 →
O16852	—	0.995	O16852 →
Q9MAY3	—	0.995	Q9MAY3 →
Q9M7Q7	—	0.994	Q9M7Q7 →
O82134	—	0.993	O82134 →
P24314	—	0.992	P24314 →
Q00268	—	0.992	Q00268 →
Q03392	—	0.991	Q03392 →
P22177	—	0.991	P22177 →
Q43266	—	0.989	Q43266 →
O02115	—	0.989	O02115 →
Q9VIT0	—	0.986	Q9VIT0 →